Rasagiline for Gait Treatment
Information source: Tel-Aviv Sourasky Medical Center
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Parkinson Disease
Status: Not yet recruiting
Sponsored by: Tel-Aviv Sourasky Medical Center
Gait disturbances are very common and are a major cause for losing of independency in
patients with advanced Parkinson's Disease (PD). The medical treatment of gait disturbances
in advanced PD is very difficult and in many cases the classical dopaminergic treatment has
no clinical benefit or even can worsen the instability and increase falls. Rasagiline, a new
MAO-B inhibitor who has recently been approved all over the world for the treatment of early
and late stages PD has been suggested to have a special effect of gait in patients with
advanced PD (LARGO sub-study).
Official title: Rasagiline for the Treatment of Gait Disturbances in Patients With ParkinsonīS Disease (PD): an Open Label Study
Study design: Observational Model: Case-Only
Minimum age: 50 Years.
Maximum age: 85 Years.
- Patients with PD who experience motor response fluctuations and have gait
disturbances at ON and OFF (TUaG >10 secs in ON and 14 secs in OFF) treated with a
stable dose of antiparkinsonian medications for the last month. Patients must be able
to identify both situations
- Able to walk for 2 minutes at the OFF and ON state
- Non-demented (MMSE= or > to25)
- Severe orthopedic problems
- Orthostatic hypotension on basal visit
- Severe, troublesome ON dyskinesias
- Dementia (MMSE <25)
- Major depression
- Active psychosis or on anti-psychotic medications
- Patients who are unlikely to complete the full protocol.
- Patients who have tried rasagiline and stopped because of side effects or lack of
- Treatment with selegiline for the last 2 months
- Any contraindication according SmPC
Locations and Contacts
Starting date: May 2010
Last updated: April 1, 2010